BioMarin to Acquire Amicus Therapeutics for $4.8 Billion Following Mixed Q4 Results

Key Facts

1Amicus missed Q4 earnings estimates, but revenues beat expectations driven by strong sales of Galafold and Pombiliti.

2BioMarin is set to acquire Amicus Therapeutics for $4.8 billion.

BioMarin Pharmaceutical has reached a definitive agreement to acquire Amicus Therapeutics in a deal valued at approximately $4.8 billion. The announcement comes as Amicus reported mixed financial results for the fourth quarter, where it missed earnings estimates but exceeded revenue expectations. Revenue growth was primarily driven by the strong performance of its rare disease treatments, Galafold and Pombiliti. This strategic acquisition is expected to consolidate BioMarin's position in the biotechnology sector and expand its portfolio of genetic medicines. Despite the earnings miss, the substantial acquisition premium is likely to drive positive sentiment for Amicus shareholders. Market analysts view this move as a significant consolidation within the biotech industry that underscores the value of specialized rare disease portfolios.